<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39370961</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1398-9995</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Allergy</Title><ISOAbbreviation>Allergy</ISOAbbreviation></Journal><ArticleTitle>Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/all.16351</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hereditary angioedema (HAE) is a chronic, unpredictable disease. Long-term prophylactic treatments that offer durable efficacy, safety, and convenience are required to assist patients in achieving complete disease control, per international guidelines. We report an interim analysis of an ongoing phase 3 (VANGUARD) open-label extension (OLE) study evaluating the long-term safety and efficacy of garadacimab for HAE prophylaxis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adults and adolescents aged ≥12 years with HAE previously participating in phase 2 and pivotal phase 3 (VANGUARD) studies were rolled over to an OLE, alongside newly enrolled patients. Patients received garadacimab 200 mg subcutaneously, once monthly for ≥12 months. The primary endpoint was treatment-emergent adverse events (TEAEs) in patients with C1 inhibitor deficiency/dysfunction.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At data cut-off (February 13, 2023; N = 161), median (interquartile range) exposure was 13.8 months (11.9-16.3). For the primary endpoint, 133/159 patients experienced ≥1 TEAE (524 events), equivalent to 0.23 events/administration and 2.84 events/patient-year. Garadacimab-related TEAEs (13% of patients, 52 events) were most commonly injection-site reactions (ISRs). No deaths occurred. One patient discontinued treatment due to garadacimab-related moderate ISR. Most TEAEs were mild/moderate; three events were serious (COVID-19, two events; abdominal HAE attack, one event) and not garadacimab related. No abnormal bleeding, thromboembolic, severe hypersensitivity, or anaphylactic events were observed. Mean HAE attack rate decreased by 95% from the run-in period; 60% of patients were attack-free. Almost all patients (93%) rated their response to garadacimab as "good" or "excellent."</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Garadacimab has a favorable safety profile suitable for long-term use and provides durable protection against HAE attacks.</AbstractText><CopyrightInformation>© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reshef</LastName><ForeName>Avner</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3324-7072</Identifier><AffiliationInfo><Affiliation>Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Connie</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8951-8903</Identifier><AffiliationInfo><Affiliation>Research Solutions of Arizona, Litchfield Park, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katelaris</LastName><ForeName>Constance H</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0002-4412-1336</Identifier><AffiliationInfo><Affiliation>Allergy and Immunology Unit, Campbelltown Hospital and Western Sydney University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Philip H</ForeName><Initials>PH</Initials><Identifier Source="ORCID">0000-0002-9155-9162</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magerl</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9218-5468</Identifier><AffiliationInfo><Affiliation>Institute of Allergology, Charité - University Medicine Berlin (joint medical faculty of Free University of Berlin and Humboldt University of Berlin), Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamagami</LastName><ForeName>Keiko</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9099-7673</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Osaka City General Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guilarte</LastName><ForeName>Mar</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7242-9584</Identifier><AffiliationInfo><Affiliation>Allergology Department, Vall d'Hebron University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keith</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><Identifier Source="ORCID">0000-0002-5644-1855</Identifier><AffiliationInfo><Affiliation>McMaster University Medical Centre, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Jonathan A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-3476-1196</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bernstein Clinical Research Center, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawo</LastName><ForeName>John-Philip</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-4321-176X</Identifier><AffiliationInfo><Affiliation>CSL Innovation GmbH, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shetty</LastName><ForeName>Harsha</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CSL Behring, King of Prussia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollen</LastName><ForeName>Maressa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CSL Behring, King of Prussia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieman</LastName><ForeName>Lolis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CSL Behring, King of Prussia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>Tim J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-7774-4855</Identifier><AffiliationInfo><Affiliation>Allergy, Asthma and Immunology, Department of Medicine and Pediatrics, Penn State University, Hershey, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vinmec Times City International Hospital, Hanoi, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>VANGUARD Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CSL Behring</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Allergy</MedlineTA><NlmUniqueID>7804028</NlmUniqueID><ISSNLinking>0105-4538</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">factor XIIa</Keyword><Keyword MajorTopicYN="N">garadacimab</Keyword><Keyword MajorTopicYN="N">hereditary angioedema</Keyword><Keyword MajorTopicYN="N">long‐term prophylaxis</Keyword><Keyword MajorTopicYN="N">monoclonal antibody</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39370961</ArticleId><ArticleId IdType="doi">10.1111/all.16351</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Zanichelli A, Arcoleo F, Barca MP, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis. 2015;10:11.</Citation></Reference><Reference><Citation>Aygören‐Pürsün E, Magerl M, Maetzel A, Maurer M. Epidemiology of bradykinin‐mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018;13(1):73.</Citation></Reference><Reference><Citation>Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41(Suppl 1):S8‐S13.</Citation></Reference><Reference><Citation>Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema‐the 2021 revision and update. Allergy. 2022;77(7):1961‐1990.</Citation></Reference><Reference><Citation>Bygum A. Hereditary angio‐oedema in Denmark: a nationwide survey. Br J Dermatol. 2009;161(5):1153‐1158.</Citation></Reference><Reference><Citation>Agostoni A, Cicardi M. Hereditary and acquired C1‐inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992;71(4):206‐215.</Citation></Reference><Reference><Citation>Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132‐150.e3.</Citation></Reference><Reference><Citation>Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329‐336.</Citation></Reference><Reference><Citation>Aygören‐Pürsün E, Bygum A, Beusterien K, et al. Estimation of EuroQol 5‐dimensions health status utility values in hereditary angioedema. Patient Prefer Adherence. 2016;10:1699‐1707.</Citation></Reference><Reference><Citation>Banerji A, Davis KH, Brown TM, et al. Patient‐reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600‐607.</Citation></Reference><Reference><Citation>Wedner HJ, Aygören‐Pürsün E, Bernstein J, et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX‐2 through 48 weeks (part 2). J Allergy Clin Immunol Pract. 2021;9(6):2305‐2314.e4.</Citation></Reference><Reference><Citation>Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108‐2121.</Citation></Reference><Reference><Citation>Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long‐term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022;11(11):CD013403.</Citation></Reference><Reference><Citation>Zanichelli A, Montinaro V, Triggiani M, Arcoleo F, Visigalli D, Cancian M. Emerging drugs for the treatment of hereditary angioedema due to C1‐inhibitor deficiency. Expert Opin Emerg Drugs. 2022;27(2):103‐110.</Citation></Reference><Reference><Citation>Craig TJ, Reshef A, Li HH, et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2023;401(10382):1079‐1090.</Citation></Reference><Reference><Citation>Craig T, Magerl M, Levy DS, et al. Prophylactic use of an anti‐activated factor XII monoclonal antibody, garadacimab, for patients with C1‐esterase inhibitor‐deficient hereditary angioedema: a randomised, double‐blind, placebo‐controlled, phase 2 trial. Lancet. 2022;399(10328):945‐955.</Citation></Reference><Reference><Citation>Valerieva A, Longhurst HJ. Treatment of hereditary angioedema‐single or multiple pathways to the rescue. Front Allergy. 2022;3:952233.</Citation></Reference><Reference><Citation>Long‐term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks. 2024 Accessed June 25, 2024. https://clinicaltrials.gov/study/NCT04739059</Citation></Reference><Reference><Citation>US Food and Drug Administration. E1A the extent of population exposure to assess clinical safety: for drugs intended for long‐term treatment of non‐life‐threatening conditions. 1995 Accessed March 19, 2024. https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/e1a‐extent‐population‐exposure‐assess‐clinical‐safety‐drugs‐intended‐long‐term‐treatment‐non‐life</Citation></Reference><Reference><Citation>Fernandes HD, Newton S, Rodrigues JM. Factor XII deficiency mimicking bleeding diathesis: a unique presentation and diagnostic pitfall. Cureus. 2018;10(6):e2817.</Citation></Reference><Reference><Citation>Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor XII. Blood. 2012;120(22):4296‐4303.</Citation></Reference><Reference><Citation>Lammle B, Wuillemin WA, Huber I, et al. Thromboembolism and bleeding tendency in congenital factor XII deficiency–a study on 74 subjects from 14 Swiss families. Thromb Haemost. 1991;65(2):117‐121.</Citation></Reference><Reference><Citation>Farkas H, Stobiecki M, Peter J, et al. Long‐term safety and effectiveness of berotralstat for hereditary angioedema: the open‐label APeX‐S study. Clin Transl Allergy. 2021;11(4):e12035.</Citation></Reference><Reference><Citation>Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo‐controlled phase III extension trial of the long‐term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 2023;75(2):253‐265.</Citation></Reference><Reference><Citation>Xu M, Zhu X, Wu J, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double‐blind, placebo‐controlled phase 1b/2 study. BMC Med. 2022;20(1):13.</Citation></Reference><Reference><Citation>Papi A, Stapleton RD, Shore PM, et al. Efficacy and safety of garadacimab in combination with standard of care treatment in patients with severe COVID‐19. Lung. 2023;201(2):159‐170.</Citation></Reference><Reference><Citation>Zuraw B, Lumry WR, Johnston DT, et al. Oral once‐daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double‐blind, placebo‐controlled phase 3 trial. J Allergy Clin Immunol. 2021;148(1):164‐172.e9.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>